| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) |
| Indication |
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas. |
| Pharmacology |
Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins. |
| Toxicity |
The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hepatic and rapid with active metabolites. Metabolites may persist in the plasma for several days. |
| Absorption |
5 to 28% bioavailability |
| Half Life |
15-30 minutes |
| Protein Binding |
80% |
| Elimination |
Approximately 60% to 70% of a total dose is excreted in the urine in 96 hours and about 10% as respiratory CO2. |
| External Links |
|